Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2895000 | 0.94 | PPARG (0.44) | PPARGTRPV1MAPTKDM4ETDP1 | |
| SCHEMBL2899203 | 0.91 | KDM4E (0.47) | PPARGMAPTKDM4ETDP1L3MBTL1 | |
| SCHEMBL941019 | 0.89 | DGAT1 (0.40) | TRPV1RAF1BRAFGRIN1GRIN2B | |
| SCHEMBL2895761 | 0.88 | F10 (0.43) | TRPV1CCR2MAOB | |
| SCHEMBL940147 | 0.88 | PPARG (0.46) | PPARGTRPV1MAPTKDM4ERAF1 | |
| SCHEMBL1099691 | 0.88 | TRPV1 (0.43) | PPARGTRPV1MAPTKDM4ETDP1 | |
| SCHEMBL1100721 | 0.86 | PPARG (0.45) | PPARGTRPV1MAPTKDM4ERAF1 | |
| SCHEMBL939898 | 0.85 | ECE1 (0.40) | TRPV1RAF1BRAFGRIN1GRIN2B | |
| SCHEMBL9104157 | 0.85 | PPARG (0.45) | PPARGTRPV1MAPTKDM4ERAF1 | |
| SCHEMBL1100633 | 0.85 | RAF1 (0.43) | PPARGTRPV1MAPTKDM4ERAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586573-B2 | N-(Aminoheteroaryl)-1H-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof | SANOFI (FR) | 2013-11-19 | — | — | US | disclosed |
| US-20100286119-A1 | N-(Aminoheteroaryl)-1H-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2010-11-11 | — | — | US | disclosed |
| US-7786104-B2 | N-(aminoheteroaryl)-1H-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2010-08-31 | — | — | US | disclosed |
| EP-2049525-B1 | N-(AMINOHETEROARYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, AND PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI AVENTIS (FR) | 2009-12-30 | — | — | EP | disclosed |
| US-20090156573-A1 | N-(Aminoheteroaryl)-1H-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286119-A1 | N-(Aminoheteroaryl)-1H-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof | IDO1, IDO2, TPH1 | PPARG 1669/4885TRPV1 1762/4885MAPT 2841/4885 |
| US-20090156573-A1 | N-(Aminoheteroaryl)-1H-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof | IDO1, IDO2, TPH1 | PPARG 1669/4885TRPV1 1762/4885MAPT 2841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.